Panacea Biotec Limited , a prominent player in the pharmaceutical industry, has announced a significant change in its top management. Devender Gupta, who held the dual role of Chief Financial Officer (CFO) and Head of Information Technology, has tendered his resignation from the company.

Key Details of the Resignation

• Reason for Departure: Personal reasons
• Last Working Day: December 15, 2025
• Interim Arrangement: Amit Gupta, General Manager-Accounts Finance, will take charge of the accounts and finance function

Impact on Company Structure

Devender Gupta's departure marks a significant change for Panacea Biotec, as he was not only the CFO but also a Key Managerial Personnel (KMP) of the company. His role encompassed critical responsibilities in financial management and information technology leadership.

Company's Response

The company has accepted Gupta's resignation and expressed its appreciation for his services and contributions during his tenure as CFO. This gesture indicates an amicable separation and acknowledges the value Gupta brought to his role.

Financial Context

While the resignation of a CFO is a significant event, it's important to consider the company's financial context. Based on the most recent balance sheet data:

The company has shown growth in total assets and a significant increase in current assets over the past year, despite a slight decrease in total equity. This financial backdrop provides context for the management change.

Looking Ahead

As Panacea Biotec navigates this transition, the appointment of Amit Gupta to oversee the accounts and finance function suggests a focus on maintaining continuity in financial operations. The company may be looking to fill the CFO position permanently in the coming months.

Investors and stakeholders will be watching closely to see how this change in leadership might affect Panacea Biotec's financial strategies and performance in the future.

Panacea Biotec , a prominent player in the Indian pharmaceutical sector, has reported its financial results for the second quarter, revealing a significant increase in net loss and a decline in revenue.

Financial Performance Overview

Key Highlights

• Widened Net Loss: Panacea Biotec's consolidated net loss for the quarter increased to ₹139.00 million, nearly tripling from ₹48.00 million in the same period last year.

• Revenue Decline: The company experienced a year-over-year revenue decline, with Q2 revenue dropping to ₹1.40 billion from ₹1.47 billion in the previous year.

• EBITDA Deterioration: The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) shifted from a positive ₹70.00 million in the prior year's quarter to a loss of ₹178.00 million.

Operational Performance

The substantial shift in EBITDA from a gain to a significant loss indicates a marked deterioration in Panacea Biotec's operational performance. This change suggests the company may be facing challenges in managing its operating costs effectively or experiencing pressure on its profit margins.

The widening net loss, coupled with declining revenue, points to a challenging quarter for Panacea Biotec. These results may prompt investors and analysts to closely monitor the company's future strategies and performance in the coming quarters.

As the pharmaceutical sector continues to evolve, Panacea Biotec's management may need to address these financial challenges and explore avenues for revenue growth and cost optimization to improve its financial health.